Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879792 | 0.92 | — | — | |
| SCHEMBL4877765 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2POLBADRB2HTTMEN1 | |
| SCHEMBL4902728 | 0.84 | ACSS2 (0.32) | ACSS2 | |
| SCHEMBL4887120 | 0.84 | KCNH2 (0.35) | SMN1; SMN2POLBADRB2HTTTSHR | |
| SCHEMBL4905168 | 0.82 | TSHR (0.35) | SMN1; SMN2POLBADRB2HTTTSHR | |
| SCHEMBL4875980 | 0.80 | TSHR (0.33) | SMN1; SMN2POLBADRB2HTTTSHR | |
| SCHEMBL4902680 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL4882617 | 0.76 | KCNH2 (0.34) | — | |
| SCHEMBL4902602 | 0.75 | KCNH2 (0.32) | ACSS2 | |
| SCHEMBL4901053 | 0.74 | TSHR (0.37) | TSHRACSS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | PFIZER INC | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176919-A1 | Imidazole Derivatives As Enzyme Reverse Transcriptase Modulators | POLRMT, POLR1G, POLR2A | SMN1; SMN2 1992/4885POLB 13/4885ADRB2 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.